Aratana Therapeutics to Participate at Three Upcoming Investment Conferences

LEAWOOD, Kan., May 16, 2017 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, plans to present at three upcoming investor conferences, including:

2017 Stifel Dental and Veterinary Conference in New York CityWednesday, May 31 at 3:35 p.m. ETListen to the Stifel webcast

Jefferies 2017 Global Healthcare Conference in New York CityWednesday, June 7, 2017 at 3:00 p.m. ET Listen to the Jefferies webcast

William Blair 2017 Growth Stock Conference in ChicagoWednesday, June 14, 2017 at 9:40 a.m. ET Listen to the William Blair webcast

Interested parties may listen live or access the audio link for up to 90 days after the meeting. Presentation slides from the conference will also be available in the Aratana Investor Room.

About Aratana TherapeuticsAratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to dogs and cats in a capital and time efficient manner. The company's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Contacts For investor inquires: Craig Tooman[email protected] (913) 353-1026

For media inquiries: Rachel Reiff[email protected] (913) 353-1050

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aratana-therapeutics-to-participate-at-three-upcoming-investment-conferences-300457700.html

SOURCE Aratana Therapeutics, Inc.